Literature DB >> 6114446

Evidence for a growth hormone releasing factor mediating alpha-adrenergic influence on growth hormone secretion in the rat.

S Eden, E Eriksson, J B Martin, K Modigh.   

Abstract

The effects of adrenergic receptor agonists on GH secretion were studied in adult, male rats pretreated with reserpine and somatostatin antiserum. Frequent blood samples were obtained from intra-aortic cannulae. Plasma GH was determined by radioimmunoassay. Reserpine (10 mg/kg i.p.) caused a complete suppression of the normal, pulsatile secretion of GH in all animals. Administration of somatostatin antiserum resulted in rapid elevations of plasma GH in reserpine-pretreated rats with peak levels at 30 min. GH levels then fell but remained slightly elevated for the duration of the sampling period (8 h). Apomorphine (0.5 mg/kg i.p.) had no effect on plasma GH levels, whereas clonidine (0.5 mg/kg i.p.) induced release of GH in both antiserum treated and control rats. The results indicate that the alpha-adrenergic influence on the secretion of GH is mediated not by inhibition of somatostatin release but rather by effects on the release of a GHRF.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114446     DOI: 10.1159/000123196

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  10 in total

1.  Serotonergic influence on the growth hormone response to clonidine in rat.

Authors:  B Söderpalm; L Andersson; M Carlsson; K Modigh; E Eriksson
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

2.  Tolerance of the oral clonidine test in 75 pediatric patients.

Authors:  R De Angelis; C Pellini; C Petecca; F Uboldi; B di Natale
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

3.  Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine.

Authors:  F Orio; N Padovano; L Cinquanta; A Colao; B Merola; S Longobardi; E Rossi; V Esposito; F Orio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

4.  Growth-hormone releasing factor and clonidine in children with constitutional growth delay. Evidence for defective pituitary growth hormone reserve.

Authors:  C Pintor; R Puggioni; V Fanni; S G Cella; A Villa; V Locatelli; E E Müller
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

5.  Up- and down- regulation of central postsynaptic alpha 2 receptors reflected in the growth hormone response to clonidine in reserpine-pretreated rats.

Authors:  E Eriksson; S Edén; K Modigh
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 6.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease.

Authors:  R Durso; C A Tamminga; S Ruggeri; A Denaro; S Kuo; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-12       Impact factor: 10.154

8.  Evidence for a peripheral component in the sympatholytic effect of clonidine in rats.

Authors:  M J Brown; D Harland
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

9.  Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children.

Authors:  E Ghigo; S Goffi; E Mazza; E Imperiale; E Arvat; J Bellone; M Procopio; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-02       Impact factor: 4.256

10.  Effects of sex steroids on growth hormone responses to clonidine and GHRH in reserpine pretreated rats.

Authors:  E Eriksson; K Modigh; J O Jansson
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.